Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

1. Salvador, J.
2. Manso, L.
3. de la Haba, J.
4. Jaen, A.
5. Ciruelos, E.
6. de Villena, M.C.
7. Gil, M.
8. Murias, A.
9. Galan, A.
10. Jara, C.
11. Bayo, J.
12. Baena, J.M.
13. Casal, J.
14. Mel, J.R.
15. Blancas, I.
16. Sanchez Rvira, P.